PubMed Health⌕ Search

Biomedical subjects

F Iwańczak

Publications and source records attributed to F Iwańczak.

At least 19 recordsLinked to original sources
PubMed2004

High level of resistance to metronidazole and clarithromycin in Helicobacter pylori isolated from pediatric patients in Poland (1997-2001).

Resistance to metronidazole (Met), clarithromycin (Cla) and amoxycillin (Amo) was examined using H. pylori isolates from child patients before and after treatment in the period 1997-2001. The rate of Met and Cla resistance before treatment was 35.2 and 8.6%, respectively. Six weeks after treatment 48.4% of the isolated strains were resistant to Met and 17.6% to Cla. The highest rate of resistance to both antibiotics was determined in 2001 (before treatment, 46 and 15%, respectively, and after treatment, 57.8 and 26.3%, respectively). All the strains were susceptible to Amo. Strains resistant to Met were detected more frequently in girls than in boys.

Adolescent↗
PubMed2001

[Evaluation of an atypical clinical presentation for pneumonia caused by Mycoplasma pneumoniae and Chlamydia sp in children].

Mycoplasma pneumoniae and Chlamydia sp. frequently cause atypical pneumonia in children. The study aim was the analysis of clinical picture of pneumonia caused by Mycoplasma pneumoniae and Chlamydia sp. in 278 children treated in the period of 1985-1998 in the IInd Clinic of Pediatrics and Gastroenterology, Medical Academy of Wrocław. The influence of etiological factor and age of children for the clinical picture of the disease was estimated. The most characteristic clinical symptom of the atypical pneumonia in children was "staccato" cough observed in 89.9% of children. More severe course of the mycoplasmal pneumonia in comparison with that of Chlamydia origin was demonstrated. The most severe course of pneumonia was observed in infants. The afebrile course of the disease was observed in the group of Chlamydia pneumonia (in 26.3% of infants, 40% of children aged 1-6 years and 54.8% of children aged 7-15 years). None of children with mycoplasmal pneumonia had an afebrile course of the disease. The most characteristic radiological picture in children with atypical pneumonia were diffused, symmetrical interstitial inflammatory changes of the lungs. In the group of children with mycoplasmal pneumonia in over 50% of cases the enlargement of lymph nodes of the lungs hili were observed.

Adolescent↗
PubMed1995

Clinical evaluation of food allergy and food intolerance dietary treatment in children.

Dietary treatment with Humana SL (33) or Prosobee (42) was administered to 75 children at the age from 1 month to 3 years with cow's milk allergy (36), coeliac disease (9), secondary enteropathy (30). The treatment time ranged from a few days (in case of intolerance symptoms) to 12 months. In 13 children intolerance symptoms or unwillingness to take food was observed: in 4 (12%) after the application of Humana SL and in 9 (21%) after Prosobee. Lack of improvement after Prosobee treatment was observed in 4 (10%) children, and in 4 (12%) children with Humana SL. The partial or total relief of symptoms was observed in others (Humana SL-76%, Prosobee-69%). Analysis showed good results of Humana SL and Prosobee treatment of food allergy and intolerance. Both are usually well tolerated by children, however Humana SL seems to taste better and be better accepted. Intolerance symptoms or lack of improvement were most often observed in children at the age of 1-2 months.

Celiac Disease↗
PubMed1995

Bismuth concentration in blood and urine of children treated with ventrisol (polfa) preliminary study.

The bismuth concentration was measured in the blood and urine of 21 children from 8 to 17 years old (13.12 +/- 2.67) treated with Ventrisol (Polfa)-tripotassium dicitrato bismuthate (TDB). One tablet of TDB-equivalent to 120 mg Bi2O3. One tablet was given orally to the patients four times a day. Blood and urine was taken for measurement of bismuth concentration in the morning, on fasting, before the administration of Ventrisol on the 6-8 days, the 27-28 days of the therapy and in the 4-5, 8-9 weeks after TDB therapy. The reason for TDB treatment was chronic gastritis and/or duodenal ulcers, which were diagnosed by endoscopic examination. No bismuth in the blood and a very low concentration in the urine were determined in 19 children before TDB treatment. After 6-8 days of TDB treatment the bismuth concentration in the blood was 40.85 +/- 31.05 micrograms/L and 75.11 +/- 82.07 micrograms/L in the urine. In the 27-28 days of the treatment the bismuth concentration in the blood was 37.67 +/- 25.06 micrograms/L, and 163.56 +/- 181.86 micrograms/L in the urine. In the 4-5 weeks after the TDB treatment the bismuth concentration in the blood was 7.77 +/- 10.56 micrograms/L, and 15.72 +/- 9.87 micrograms/L in the urine. The bismuth concentration level in the urine rose together with the rise of the bismuth concentration level in the blood, the correlation factor was r = 0.68. No symptoms of side effects caused by the TDB treatment were observed. Before the treatment a high bismuth concentration was found in the blood of two patients. These cases are discussed later.

Adolescent↗
PubMed1989

[Cancer of the renal parenchyma in a 14-year-old girl with horseshoe kidney].

A 14-year-old girl is reported in whom carcinoma of the parenchyma of the right kidney and horseshoe kidney were diagnosed. The right kidney with the neoplasm was removed (carcinoma was in stage I of development), Histological examination demonstrated clear cell carcinoma. The patient remains under follow-up observation and two years after the operation she is well and no signs of disease have been observed.

Adenocarcinoma↗